PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.75 - 1.81
1.03 - 2.41
122.5K / 297.6K (Avg.)
-1.36 | -1.31
Shows the trajectory of a company's cash-generation capacity. Consistent growth in operating and free cash flow suggests a robust, self-funding business model—crucial for value investors seeking undervalued, cash-rich opportunities.
12.55%
Net income growth exceeding 1.5x Biotechnology median of 4.80%. Joel Greenblatt would see it as a clear outperformance relative to peers.
-4.31%
D&A shrinks yoy while Biotechnology median is 0.00%. Seth Klarman would see a short-term earnings benefit if capacity is sufficient.
-1173.94%
Deferred tax shrinks yoy while Biotechnology median is 0.00%. Seth Klarman would see potential advantage if actual tax outflows do not spike.
-7.99%
SBC declines yoy while Biotechnology median is 0.00%. Seth Klarman would see a near-term advantage in less dilution unless new hires are needed.
214.02%
Working capital of 214.02% while Biotechnology median is zero at 0.00%. Walter Schloss would check if expansions or cost inefficiencies cause that difference.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
-138.21%
AP shrinks yoy while Biotechnology median is 0.00%. Seth Klarman would see better immediate cost coverage if top-line remains intact.
259.96%
Growth of 259.96% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or unusual one-time factors behind the difference.
1173.94%
Growth of 1173.94% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or one-off revaluations explaining the difference.
18.46%
Operating cash flow growth exceeding 1.5x Biotechnology median of 5.84%. Joel Greenblatt would see a strong operational advantage vs. peers.
36.17%
CapEx growth of 36.17% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or upgrades behind the difference.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
No Data
No Data available this quarter, please select a different quarter.
36.17%
Investing flow of 36.17% while Biotechnology median is zero at 0.00%. Walter Schloss would question expansions or deals prompting that difference.
No Data
No Data available this quarter, please select a different quarter.
-70.77%
We reduce issuance yoy while Biotechnology median is 0.00%. Seth Klarman might see an advantage in preserving per-share value unless expansions are neglected.
No Data
No Data available this quarter, please select a different quarter.